Skip to main content

Table 1 Baseline characteristics of 171 patients admitted with acute decompensated heart failure

From: Direct comparison of serial B-type natriuretic peptide and NT-proBNP levels for prediction of short- and long-term outcome in acute decompensated heart failure

Clinical characteristic

Overall n= 171

One-year non-survivors n= 60

One-year survivors n= 111

P value

Female gender, number (percentage)

68 (40)

27 (45)

41 (37)

0.305

Age in years

80

84

77

< 0.001

 

(73-85)

(79-89)

(68-83)

 

Body mass index, kg/m2

26

24

27

0.001

 

(23-30)

(22-28)

(25-31)

 

Vital signs

    

   Systolic blood pressure, mm Hg

139

138.5

139.5

0.270

 

(117-156)

(111-151)

(121-157)

 

   Diastolic blood pressure, mm Hg

84

86

83

0.941

 

(70-95)

(68-94)

(71-96)

 

   Heart rate, beats per minute

88

90

87

0.641

 

(77-104)

(77-103)

(76-103)

 

Echocardiography

    

   LVEF, percentage

37

40

36

0.579

 

(25-55)

(29-51)

(25-65)

 

   LVEDD, mm

54

51

56

0.037

 

(47-61)

(46-58)

(47-65)

 

Blood test results, number (percentage)

    

   Sodium, mmol/L

139

139

139

0.854

 

(136-141)

(137-141)

(136-141)

 

   Potassium, mmol/L

4.2

4.3

4.2

0.577

 

(3.8-4.6)

(3.7-4.6)

(3.8-4.6)

 

   Creatinine, μmol/L

103

131

97

< 0.001

 

(80-142)

(92-180)

(75-125)

 

   Urea, mmol/L

10

14

9

< 0.001

 

(7-14)

(10-18)

(7-12)

 

   Glomerular filtration rate, mL/minutea

48

34

60

< 0.001

 

(33-70)

(24-48)

(41-83)

 

   ASAT, U/L

34

36

33

0.049

 

(26-45)

(28-53)

(25-42)

 

   Cardiac troponin T, μg/L

0.02

0.04

0.01

< 0.001

 

(0.01-0.04)

(0.01-0.07)

(0.01-0.02)

 

   BNP, pg/mL

1,315

1,718

973

< 0.001

 

(759-2,349)

(1,088-3,042)

(604-1,725)

 

   NT-proBNP, pg/mL

6,964

11,624

5,840

0.01

 

(3,068-14,791)

(5,722-20,597)

(2,617-11,277)

 

Co-morbidity, number (percentage)

    

   Coronary artery disease

62 (37)

37 (33)

25 (42)

0.946

   Hypertension

95 (55)

54 (49)

41 (69)

0.324

   Chronic heart failure

74 (43)

32 (53)

42 (38)

0.482

   Renal dysfunction

62 (37)

34 (57)

28 (25)

0.002

   Diabetes mellitus

48 (30)

26 (24)

22 (37)

0.355

   Symptoms, number (percentage)

    

   Dyspnea

   

0.180

NYHA II

2 (1)

0

2 (2)

 

NYHA III

69 (40)

18 (30)

51 (46)

 

NYHA IV

92 (54)

41 (69)

51 (46)

 

   Chest pain

47 (37)

16 (31)

31 (41)

0.250

   Weight gain

56 (44)

22 (42)

34 (45)

0.863

   Orthopnea

81 (63)

29 (56)

52 (68)

0.843

   Paroxysmal nocturnal dyspnea

59 (46)

16 (31)

43 (57)

0.133

Etiology of heart failure, number (percentage)

    

   Ischemic heart disease

41 (24)

10 (16)

31 (29)

0.295

   Hypertensive heart disease

60 (35)

20 (32)

40 (36)

0.815

   Valvular heart disease

40 (23)

22 (37)

18 (16)

0.161

   Idiopathic heart disease

22 (13)

4 (6)

18 (16)

0.267

   Otherb

8 (5)

4 (9)

4 (3)

0.823

Electrocardiogram, number (percentage)

    

   Sinus rhythm

83 (49)

35 (46)

25 (48)

0.822

   Atrial fibrillation/flutter

44 (26)

20 (33)

24 (21)

0.423

   QRS duration, milliseconds

112 (95-151)

125 (100-154)

110 (92-144)

0.210

Admission medication, number (percentage)

    

   Aspirin

68 (40)

23 (39)

45 (41)

0.940

   Clopidogrel

16 (10)

4 (7)

12 (11)

0.607

   Oral anticoagulation

67 (40)

25 (42)

42 (38)

0.492

   Beta-blocker

120 (70)

39 (65)

81 (73)

0.103

   ACE inhibitor

116 (68)

33 (55)

83 (75)

0.025

   Angiotensin II receptor blocker

67 (40)

18 (30)

49 (44)

0.103

   Calcium channel-blocker

68 (40)

20 (33)

48 (43)

0.341

   Diuretics

145 (85)

52 (87)

93 (84)

0.431

   Aldosterone antagonist

20 (12)

6 (10)

14 (13)

0.856

   Digoxin

10 (6)

5 (8)

5 (5)

0.274

   Nitrates

41 (24)

15(25)

26 (24)

0.836

Heart failure medication 0 to 72 hours

    

   Furosemide, mg

40 (20-80)

40 (0-60)

40 (20-100)

0.095

   Torasemide, mg

30 (10-80)

30 (20-70)

20 (0-130)

0.639

   Nitratesc, mg/24 hours

40 (15-83)

40 (20-117)

30 (10-60)

0.121

Discharge medication, number (percentage)

    

   Aspirin

61 (36)

15 (25)

46 (42)

0.033

   Clopidogrel

18 (11)

4 (7)

14 (13)

0.228

   Oral anticoagulation

73 (43)

20 (33)

53 (48)

0.070

   Beta-blocker

116 (68)

28 (47)

88 (80)

< 0.001

   ACE inhibitor

111 (65)

32 (54)

79 (71)

0.052

   Angiotensin II receptor blocker

49 (29)

9 (15)

40 (36)

0.006

   Calcium channel-blocker

30 (18)

9 (15)

21 (19)

0.617

   Diuretics

147 (86)

44 (73)

103 (93)

< 0.001

   Aldosterone antagonist

27 (16)

9 (15)

18 (16)

0.836

   Digoxin

18 11)

6 (10)

12 (11)

0.869

   Nitrates

62 (37)

22 (37)

40 (36)

0.745

  1. Values are presented as median (interquartile range) unless stated otherwise. aUsing the Cockcroft and Gault formula [29]; bincluding hypertrophic obstructive cardiomyopathy, myocarditis, and alcoholic cardiomyopathy; cusually applied transdermally. ACE, angiotensin-converting enzyme; ASAT, aspartate aminotransferase; BNP, B-type natriuretic peptide; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal B-type natriuretic peptide; NYHA, New York Heart Association.
Back to article page

Critical Care

ISSN: 1364-8535